Ken Kojo

Ken Kojo

Auto-generated profile, based on publicly available information

Ken Kojo

Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami Ward, Sagamihara, Kanagawa, 252-0329, Japan.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KYKeigo Yokoi
Keigo Yokoi
HHHiroki Harada
Hiroki Harada
KYKazuko Yokota
Kazuko Yokota
SISatoru Ishii
Satoru Ishii
TTToshimichi Tanaka
Toshimichi Tanaka
Keishi YamashitaKeishi Yamashita
Keishi Yamashita

1 July 2015 in Life Sciences
Verified
Journal Article
Closed access
TMTsutomu Minamino
Tsutomu Minamino
YIYoshiya Ito
Yoshiya Ito
HOHirotoki Ohkubo
Hirotoki Ohkubo
YSYuki Shimuzu
Yuki Shimuzu
KKKen Kojo
Ken Kojo
MMMasataka Majima
Masataka Majima

8 December 2025 in Nature Communications
Verified
Journal Article
Open access
XLXin Liu
Xin Liu
ZLZelong Liu
Zelong Liu
CZChengzhan Zhu
Chengzhan Zhu
TKTatsuya Kobayashi
Tatsuya Kobayashi
PLPin-Ji Lei
Pin-Ji Lei
Dan G DudaDan G Duda
Dan G Duda
Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1+ B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1+ B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8+ T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies.

9 July 2024 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
KKKen Kojo
Ken Kojo
TYTakahiro Yamanashi
Takahiro Yamanashi
SHShigenori Homma
Shigenori Homma
MYManabu Yamamoto
Manabu Yamamoto
TMTakuya Miura
Takuya Miura
ESEnSSURE study group collaboratives in Japan Society of Laparoscopic Colorectal Surgery
EnSSURE study group collaboratives in Japan Society of Laparoscopic Colorectal Surgery
Background: In Japan, the Endoscopic Surgical Skill Qualification System (ESSQS) is used to evaluate surgical skills essential for laparoscopic surgery, but whether surgeons with this certification as operators improve the short‐term outcomes and prognosis after rectal cancer surgery is unclear. This cohort study was designed to compare the short‐term and long‐term outcomes of laparoscopic surgery for advanced rectal cancer performed by an ESSQS‐certified surgeon versus a surgeon without ESSQS certification.Methods: The outcomes of cStage II and III rectal cancer surgery cases performed at 56 Japanese hospitals between 2014 and 2016 were retrospectively reviewed. To examine the impact of ESSQS‐certified surgeons as surgeons, the outcomes of cases with only ESSQS‐certified surgeons as operators were compared with those without involvement of ESSQS‐certified surgeons.Results: A total of 3197 cases were enrolled, with 1015 in which surgery was performed by ESSQS‐certified surgeons, and 544 in which there was no involvement of ESSQS‐certified surgeons. After propensity score matching, the ESSQS group had significantly shorter operative time (p < 0.001), a lower conversion rate to open surgery (p < 0.001), and more dissected lymph nodes (p = 0.002).Conclusion: Laparoscopic rectal surgery performed by ESSQS‐certified surgeons was significantly associated with improved short‐term outcomes. This demonstrates the utility of the ESSQS certification system.

1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
Verified
Journal Article
Open access
PDF file
NSNakamoto Shuji
Nakamoto Shuji
YIYoshiya Ito
Yoshiya Ito
TGTakuya Goto
Takuya Goto
NNNobuyuki Nishizawa
Nobuyuki Nishizawa
KKKen Kojo
Ken Kojo
MMMasataka Majima
Masataka Majima
Macrophage plasticity is essential for liver wound healing; however, the mechanisms of macrophage phenotype switch are largely unknown. Dendritic cells (DCs) are critical initiators of innate immune responses and orchestrate inflammation following hepatic injury. We have shown that PGE2/EP3 promotes liver repair after hepatic ischemia-reperfusion (I/R). The present study examined whether signaling via EP3 in DCs regulates macrophage plasticity during liver repair by subjecting EP3-deficient (EP3-/-) and wild-type (WT) mice to hepatic I/R. Compared with WT mice, EP3-/- mice showed delayed liver repair as indicated by increased levels of ALT and hepatic necrosis, which accompanied by reduced expression of hepatic growth factors. Flow cytometry analysis revealed that accumulation of Ly6Clow reparative macrophages and monocyte-derived DCs (moDCs) was suppressed in EP3-/- livers. Adoptive transfer of moDCs from EP3-/- mice resulted in impaired repair, along with increased Ly6Chigh inflammatory macrophages. When bone marrow macrophages (BMMs) co-cultured with moDCs, BMMs from WT mice, but not from EP3-/- mice up-regulated expression of genes related to a reparative macrophage phenotype. In the presence of an EP3 agonist, interleukin (IL)-13 derived from moDCs drove BMMs to increase expression of genes characteristic of a reparative macrophage phenotype. The results suggest that EP3 signaling in moDCs facilitates liver repair by inducing IL-13-mediated switching of macrophage phenotype from pro-inflammatory to pro-reparative.

10 June 2026 in Radiation Oncology
Verified
Journal Article
Open access
KKKen Kojo
Ken Kojo
TTToshimichi Tanaka
Toshimichi Tanaka
TYTakahiro Yamanashi
Takahiro Yamanashi
HMHirohisa Miura
Hirohisa Miura
KYKeigo Yokoi
Keigo Yokoi
TNTakeshi Naitoh
Takeshi Naitoh
Background: A phase I study was conducted to determine the optimal dose of irinotecan in short-course chemoradiotherapy (SCCRT) using S-1/irinotecan and short-course radiotherapy (SCRT) for the development of a new total neoadjuvant therapy (TNT) regimen that is safe, effective, and has a low patient burden for locally advanced rectal cancer (LARC). Methods: The objective of this study was to ascertain the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan in SCCRT for locally advanced rectal cancer. The assessment of dose-limiting toxicity (DLT) was conducted over a 14-day period following treatment administration. The patient received a 14-day course of chemotherapy, with S-1 administered from the first to the fifth day and from the eighth to the twelfth day. Irinotecan was administered on the first and eighth days of treatment. The radiotherapy regimen was initiated with a total dose of 25 Gy, administered in five fractions from the eighth to twelfth day. Results: Fifteen patients received SCRT in conjunction with S-1 and escalating doses of irinotecan (40–60 mg/m²). All patients completed the SCCRT protocol. At a dose of 60 mg/m², DLT occurred in all patients, thereby establishing this dosage as the MTD. At a dose of 50 mg/m², DLT was observed in two of six patients, thereby establishing this dose as the RD. The most prevalent Grade ≥ 3 adverse event was diarrhea. All patients received CapeOX-based consolidation chemotherapy. Among the 11 surgical cases, the R0 resection rate was 100%, with a pathological complete response in 27.3% and downstaging in 90.9%. Three patients demonstrated a complete clinical response and underwent non-operative management. Conclusion: The safety and feasibility of administering SCCRT with S-1/irinotecan at a 50 mg/m² irinotecan dose have been demonstrated. These findings support further investigation of this regimen in a TNT setting for rectal cancer. Trial registration: The present study was duly registered with the Japan Clinical Trials Registry (jRCT s031210461). URL: https://jrct.mhlw.go.jp/re .